Glossary
:
Legal/Privacy
:
Contact
Product Pipeline :
HIV
HIV
Hepatitis C
Influenza
Vaccine Market
Hepatitis B
Rotavirus
Mosquito diseases
Breast Cancer
HIV
PepTcell has applied its breakthrough technology to the development of a new class of T and B cell therapeutic vaccines that is effective against HIV. The synthetic vaccine comprises a number of HIV immunogenic and conserved
epitope
s.
Since 1981, HIV has infected over 60 million people worldwide, of whom more than a third have died. While progress has been made in slowing the progression of the disease in some countries, there is still no cure or prevention. It is widely believed that a vaccine against HIV/AIDS will be the most or only effective means to stop the global epidemic. The majority of candidate conventional HIV vaccines designed to date have been
antibody
based. Given the very high mutation rate of the HIV virus has meant that this approach has not shown any success over the last 10-15 years. The majority of candidate therapeutic HIV vaccines have concentrated around two main
protein
s without any work being carried out on the other 5
protein
s that make up the HIV virus. PepTcell’s HIV vaccine mainly focuses on the low mutating regions within HIV
protein
s. The
epitope
s selected have been shown to be substantially present in over 5600 different HIV strains suggesting that the vaccine should be effective against all known current mutations of the virus.
PepTcell's HIV vaccine can be quickly, easily and cost-effectively manufactured in chemical plants.
Pre-clinical proof of principle and safety studies have been completed and approval has been received to commence a Phase Ib clinical trial study in the UK.